Introduction
In our previous article, we explored the different categories of biomarkers used in cancer care, from those that signal disease risk to those that help monitor a patient’s response over time. Among these categories, one stands out as particularly central to the promise of precision oncology: the predictive biomarker.
While prognostic biomarkers tell us how a cancer is likely to behave, predictive biomarkers tell us something different and arguably more actionable. They tell us whether a specific treatment is likely to work for a specific patient. That distinction matters enormously in clinical practice, and it is what makes predictive biomarkers the foundation of truly personalized cancer care.
What Makes a Biomarker Predictive?
A predictive biomarker is a biological feature that can identify patients who are more likely to respond to a particular therapy. It does not simply describe the cancer. It connects a measurable characteristic of the tumor to an expected treatment outcome, essentially acting as a guide for which treatment path makes the most sense for that individual.
The classic example is HER2 status in breast cancer, which we touched on in a previous blog post. HER2 is a protein that, when present at abnormally high levels, acts like a stuck accelerator in a car, constantly sending signals that tell cancer cells to grow and divide. When a tumor shows this pattern, it signals that targeting HER2 directly with a drug like trastuzumab is likely to be effective. Without testing for HER2 first, patients might receive a targeted therapy they cannot benefit from, or miss out on one that could significantly improve their outcomes.
This is the core value of a predictive biomarker. It removes guesswork from treatment selection.
How Predictive Biomarkers Are Discovered
Predictive biomarkers are rarely found by accident. Their discovery typically begins in research, often emerging from clinical trials where doctors notice that certain patients respond dramatically better to a treatment than others. When that pattern keeps showing up consistently, researchers start asking why. What do those patients have in common? What is different about their tumors?
To answer that question, scientists analyze tumor tissue or blood samples from trial participants, looking for genetic changes or other molecular features that seem to be shared among the patients who responded well. Statistical methods are then used to determine whether the connection is strong enough to be meaningful, or whether it could simply be a coincidence.
The challenge is that many potential biomarkers are identified at this stage but fail to hold up under further scrutiny. A biomarker that looks promising in one study may not show the same results in another, particularly when different groups of patients or different testing methods are involved. This is a normal and important part of the scientific process, even if it means that progress can sometimes feel slow.
From Discovery to Clinical Use: The Importance of Validation
Discovering a potential predictive biomarker is only the beginning. Before it can be used to guide real treatment decisions, it needs to be rigorously validated, meaning researchers need to confirm that it works reliably and consistently across many different patients and settings.
This typically involves large clinical trials specifically designed to test the biomarker’s performance, not just the treatment itself. Researchers need to show that patients who test positive for the biomarker respond better to the treatment, and that patients who test negative do not benefit in the same way. That comparison is what makes a biomarker clinically useful.
The test used to detect the biomarker also needs to be dependable. It should produce consistent results whether it is run in a hospital laboratory in Calgary or a research centre in Singapore. If the test performs differently depending on where or how it is used, the biomarker loses its practical value.
In many cases, a predictive biomarker and its companion test are reviewed and approved together by regulatory agencies, such as Health Canada or the US Food and Drug Administration, before they become part of routine clinical practice.
Examples in Practice
Several predictive biomarkers are now well established in oncology and used routinely to guide treatment decisions.
In lung cancer, a gene called EGFR can develop changes, known as mutations, that cause it to behave abnormally and drive tumor growth. When a lung tumor carries these mutations, patients tend to respond significantly better to a class of targeted drugs called EGFR inhibitors than patients whose tumors do not carry them. Testing for EGFR mutations is now a standard part of the workup for lung cancer, helping oncologists decide whether this type of targeted therapy is the right fit.
In melanoma, a skin cancer, a specific mutation in a gene called BRAF, most commonly the V600E mutation, causes a protein involved in cell growth to become permanently switched on. Drugs designed to block this mutated protein can be highly effective, but only in patients whose tumors carry that particular change. Testing for the BRAF mutation helps oncologists determine upfront whether this targeted approach is appropriate.
Immunotherapy is another area where predictive biomarkers play an important role. These treatments work by helping the immune system recognize and attack cancer cells, but they do not work equally well for everyone. One marker that helps predict who might benefit is a protein called PD-L1. Some tumors use this protein as a kind of disguise, essentially telling the immune system to stand down. Drugs that block this signal can lift that disguise and allow the immune system to respond. Tumors that produce more PD-L1 tend to be more likely to respond to this type of treatment, though it is not a perfect predictor on its own.
Another marker used in immunotherapy decisions relates to how stable a tumor’s DNA is. Some tumors have a reduced ability to repair errors in their DNA, which means they accumulate a large number of genetic changes over time. This instability, somewhat counterintuitively, can actually make those tumors more recognizable to the immune system and more responsive to immunotherapy. Testing for this pattern is now used across several cancer types to help identify patients who may benefit from these treatments.
The Challenges of Predictive Biomarkers
Despite their promise, predictive biomarkers come with real limitations that are worth understanding.
One of the most significant is that tumors are not as uniform as they might appear. Different regions of the same tumor can have different molecular features, and cancer cells that have spread to other parts of the body may look biologically different from the original tumor. A single biopsy captures only a snapshot of that complexity. This means that a biomarker identified in one sample may not fully represent what is happening throughout the entire cancer.
Resistance is another challenge that clinicians encounter regularly. Even when a predictive biomarker correctly identifies a patient as likely to respond to a treatment, cancers can change over time. New mutations can emerge under treatment pressure, allowing the tumor to find workarounds and continue growing. This is one reason why monitoring patients throughout treatment, not just at the start, is so important.
Finally, not all cancers are driven by a single molecular change. In tumors where multiple biological pathways are involved, identifying one predictive biomarker may not be enough to guide treatment selection on its own. Precision oncology is increasingly moving toward looking at multiple markers together to build a more complete picture.
Conclusion
Predictive biomarkers represent one of the most important advances in modern oncology. By connecting the biology of a tumor to the likelihood of treatment response, they give physicians a way to make more confident, evidence-based decisions and to spare patients from treatments that are unlikely to help them.
As testing technologies continue to improve, more predictive biomarkers are being discovered and validated. The field is steadily moving toward a future where the question is not just what type of cancer a patient has, but what is driving it and what that means for treatment.
In our next article, we will take a deeper look at gene expression panels, diagnostic tools that go beyond individual mutations to capture how a tumor is behaving as a whole, and how that information is changing treatment decisions in cancers like breast cancer.